Last updated: September 2, 2026
Sacituzumab govitecan-hziy, marketed by Gilead Sciences as Trodelvy, is a Trop-2-directed antibody-drug conjugate approved for multiple metastatic breast cancer settings. Product sales increased from approximately $105 million in 2020 to more than $1 billion annually by 2023. The commercial case depends on expansion into earlier-line breast cancer, preservation of market share against trastuzumab deruxtecan and datopotamab deruxtecan, and the ability to recover from the failed urothelial-cancer confirmatory study.
Gilead paid approximately $21 billion to acquire Immunomedics in 2020, excluding potential contingent value rights. The transaction gave Gilead a marketed oncology asset with multibillion-dollar sales potential but also exposed the company to high clinical concentration, manufacturing complexity, and intense competition in the Trop-2 and antibody-drug conjugate markets.
What is sacituzumab govitecan-hziy and how does Trodelvy work?
Trodelvy is a Trop-2-directed antibody-drug conjugate consisting of:
| Component |
Description |
| Antibody |
Humanized anti-Trop-2 antibody, hRS7 |
| Linker |
Hydrolysable linker designed to release the payload |
| Payload |
SN-38, the active metabolite of irinotecan |
| Drug-to-antibody ratio |
Approximately 7.6 |
| Administration |
Intravenous infusion |
| BLA |
FDA BLA 761115 |
| Manufacturer |
Gilead Sciences, following its acquisition of Immunomedics |
The drug binds Trop-2 on tumor cells and delivers SN-38 intracellularly. Its high drug-to-antibody ratio supports payload delivery but contributes to clinically important neutropenia, diarrhea, anemia, nausea, and infusion-related reactions. These adverse events influence physician selection, supportive-care requirements, treatment persistence, and comparative value against other antibody-drug conjugates.
Trodelvy’s primary commercial markets are metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative metastatic breast cancer, and selected urothelial-cancer patients. The U.S. label and indication history have changed as confirmatory data became available.
What FDA approvals and exclusivity periods apply to Trodelvy?
Trodelvy received accelerated FDA approval in April 2020 for adults with metastatic triple-negative breast cancer who had received at least two prior systemic therapies. The FDA granted regular approval for this indication in April 2021 after confirmatory ASCENT data supported progression-free and overall-survival benefits.[1,2]
Key FDA milestones
| Date |
Regulatory event |
| April 2020 |
Accelerated approval for metastatic triple-negative breast cancer after at least two prior therapies |
| April 2021 |
Regular approval for metastatic triple-negative breast cancer |
| April 2021 |
Accelerated approval for locally advanced or metastatic urothelial cancer after platinum chemotherapy and a PD-1/PD-L1 inhibitor |
| December 2022 |
Accelerated approval for HR-positive/HER2-negative metastatic breast cancer after endocrine therapy and at least two additional systemic therapies |
| 2023 |
FDA expanded the HR-positive/HER2-negative label to include patients who received at least one endocrine-based therapy and at least two systemic therapies in the metastatic setting |
| 2024 |
Gilead reported failure of the TROPiCS-04 confirmatory study in metastatic urothelial cancer and initiated withdrawal of that indication |
As a biologic, Trodelvy is subject to the Biologics Price Competition and Innovation Act rather than the small-molecule Hatch-Waxman pathway. The reference product has 12 years of U.S. reference-product exclusivity from first licensure under the BPCIA. On the April 2020 approval date, the statutory period points to April 2032, subject to the legal treatment of pediatric exclusivity, patent rights, and any regulatory changes.[3]
No conventional generic product can enter through an abbreviated new drug application. A future competitor would generally pursue a biosimilar or interchangeable biosimilar application, although the complexity of an antibody-drug conjugate can make analytical and clinical comparability more difficult than for a conventional monoclonal antibody.
How much revenue does Trodelvy generate?
Trodelvy moved from launch-stage sales to a blockbuster oncology product within four years.
| Fiscal year |
Approximate Trodelvy product sales |
Commercial position |
| 2020 |
$105 million |
Partial-year launch |
| 2021 |
$380 million |
Expansion after regular TNBC approval |
| 2022 |
$680 million |
Broader U.S. and international adoption |
| 2023 |
$1.05 billion |
First year above the $1 billion threshold |
| 2024 |
Approximately $1.1 billion to $1.2 billion |
Growth moderated by competition and urothelial-cancer pressure |
Gilead’s annual reports identify Trodelvy as one of the company’s principal non-HIV growth products. Sales growth has been driven by increased use in metastatic breast cancer, additional geographic launches, and wider physician familiarity with Trop-2-directed therapy.[4,5]
The financial trajectory is important because the acquisition price implied a much larger long-term opportunity than current sales. Gilead initially projected peak Trodelvy revenue in the multibillion-dollar range. The product has reached commercial scale, but its path toward a substantially larger revenue base now depends on earlier-line breast-cancer indications and improved positioning against competing antibody-drug conjugates.
What drove Trodelvy’s commercial growth?
Triple-negative breast cancer
The ASCENT trial established Trodelvy as a major treatment option for patients with previously treated metastatic triple-negative breast cancer. The drug improved median progression-free survival and overall survival compared with physician’s-choice chemotherapy.[2]
This indication remains the commercial foundation of the franchise. The addressable population is clinically important but smaller than the broader HER2-negative breast cancer market. Treatment sequencing is also affected by pembrolizumab, trastuzumab deruxtecan in HER2-low disease, sacituzumab alternatives, and chemotherapy.
HR-positive/HER2-negative breast cancer
The HR-positive/HER2-negative label expansion materially increased the addressable population. This segment is larger than metastatic triple-negative breast cancer, but it is more competitive and contains multiple established endocrine, targeted, and antibody-drug conjugate treatment options.
Trodelvy competes with trastuzumab deruxtecan, marketed as Enhertu, in HER2-low and HER2-ultralow populations. The clinical and commercial distinction between Trop-2 targeting and HER2 targeting is narrowing because both products are increasingly used in overlapping HER2-negative populations.
Urothelial cancer
Trodelvy received accelerated approval in urothelial cancer based on response data. The confirmatory TROPiCS-04 study did not demonstrate the required overall-survival benefit. Gilead announced that it would withdraw the urothelial-cancer indication in the United States and other markets.[6]
The withdrawal reduces the total addressable market and weakens the original acquisition thesis. It also removes a potential growth driver that could have diversified Trodelvy beyond breast cancer.
How does Trodelvy compare with competing antibody-drug conjugates?
| Product |
Target |
Payload |
Main overlapping market |
Strategic position |
| Trodelvy |
Trop-2 |
SN-38 |
TNBC and HR-positive/HER2-negative breast cancer |
Broad Trop-2 breast-cancer platform |
| Enhertu |
HER2 |
Topoisomerase I inhibitor derivative |
HER2-positive, HER2-low, and HER2-ultralow breast cancer |
Strong efficacy and broad HER2 segmentation |
| Datopotamab deruxtecan |
Trop-2 |
Topoisomerase I inhibitor derivative |
HR-positive/HER2-negative and TNBC breast cancer |
Direct Trop-2 competitor from AstraZeneca and Daiichi Sankyo |
| Padcev |
Nectin-4 |
MMAE |
Urothelial cancer |
Stronger position in urothelial cancer after Trodelvy’s setback |
| Sacituzumab govitecan biosimilar or follow-on |
Trop-2 |
SN-38 or comparable payload |
Future breast-cancer markets |
No approved U.S. competitor identified as of 2024 |
Trodelvy’s principal clinical vulnerability is direct and indirect competition from other topoisomerase-I antibody-drug conjugates. Enhertu has generated strong data in HER2-low disease, while datopotamab deruxtecan is designed to compete directly in Trop-2-expressing breast cancer.
Trodelvy retains potential advantages from clinical experience, established physician use, and a broad evidence base in triple-negative disease. Its disadvantages include toxicity management, infusion delivery, and the need to defend efficacy in increasingly earlier treatment lines.
When does Trodelvy lose exclusivity?
The practical U.S. loss-of-exclusivity date is likely to be determined by the interaction of biologic exclusivity, patent rights, and biosimilar litigation.
| Exclusivity layer |
Likely timing or issue |
| FDA reference-product exclusivity |
Approximately April 2032, based on 12 years from the April 2020 BLA approval |
| Composition and antibody patents |
Potentially extending into the early-to-mid 2030s, depending on patent family, terminal disclaimers, and patent-term adjustment |
| Formulation and conjugation patents |
May extend beyond core composition claims if valid and enforceable |
| Biosimilar competition |
No approved U.S. biosimilar identified as of 2024 |
| Paragraph IV challenge |
Not the standard pathway because Trodelvy is a biologic |
| Orange Book status |
Not the primary U.S. patent-listing framework for the BLA |
The core legal risk is not only expiration. It is whether a biosimilar applicant can establish sufficient analytical similarity for the antibody, linker, conjugation profile, drug-to-antibody ratio, impurities, and pharmacokinetic behavior. Manufacturing consistency is a material barrier for antibody-drug conjugates.
What patents and intellectual-property rights protect Trodelvy?
Trodelvy’s intellectual-property estate is expected to include several layers:
- The anti-Trop-2 antibody and antibody variants.
- Antibody-drug conjugates using the hRS7 antibody.
- Linker chemistry connecting the antibody to SN-38.
- Drug-to-antibody ratio and conjugation processes.
- Pharmaceutical compositions and intravenous formulations.
- Methods of treating breast cancer and other Trop-2-expressing tumors.
- Manufacturing and purification processes.
The strongest protection generally comes from claims that cover the specific antibody, the antibody-SN-38 conjugate, and the manufacturing process. Method-of-use patents can protect particular treatment lines, biomarker-defined populations, or combination regimens, but their value depends on claim scope and infringement evidence.
Trodelvy does not have the same Orange Book patent-certification structure as an orally administered small molecule. FDA biologic exclusivity and patent litigation under the BPCIA are more relevant than a standard Paragraph IV campaign. Publicly available regulatory documents do not establish a single definitive expiration date for every enforceable patent claim. The commercial assessment should therefore distinguish statutory biologic exclusivity from patent-term expiry.
Which companies are challenging Trodelvy commercially?
The main competitive threats are:
- Daiichi Sankyo and AstraZeneca, through Enhertu and datopotamab deruxtecan.
- Roche and other developers of HER2-directed antibody-drug conjugates.
- Companies developing Trop-2-directed ADCs with alternative payloads.
- Generic chemotherapy manufacturers, which compete on price in later-line treatment.
- Biosimilar developers that may target the antibody-drug conjugate after the BPCIA exclusivity period.
The most important challenge is datopotamab deruxtecan because it targets the same antigen and uses a topoisomerase-I payload class. The products may compete for the same oncologists, treatment lines, and payer budgets even if their labels are not identical.
What is the outlook for Trodelvy’s financial trajectory?
Trodelvy has moved into a mature growth phase. The next phase is less likely to be driven by simple geographic expansion and more likely to depend on label sequencing, comparative efficacy, and use in earlier-line breast cancer.
Upside drivers
- Positive phase 3 results in earlier-line metastatic TNBC.
- Expansion into neoadjuvant or adjuvant breast cancer.
- Increased use in HER2-low or biomarker-defined populations.
- Combination studies with immunotherapy or targeted agents.
- International reimbursement expansion.
- Improved manufacturing yields and supply reliability.
Downside drivers
- Continued Enhertu share gains.
- Direct competition from datopotamab deruxtecan.
- Failure of additional confirmatory studies.
- Neutropenia and diarrhea limiting treatment duration.
- Payer pressure on high-cost ADC sequencing.
- Loss of the urothelial indication.
- Biosimilar or follow-on competition after 2032.
The acquisition economics are defensible only if Trodelvy sustains more than $1 billion in annual sales and expands into larger breast-cancer populations. The urothelial setback lowers the probability of reaching the highest original peak-sales scenarios. A stable franchise in the $1 billion to $2 billion range remains commercially plausible if Gilead maintains share in TNBC and secures earlier-line adoption.
What generic entry risks exist for Trodelvy?
Near-term U.S. generic entry risk is low because Trodelvy is a biologic and lacks an ordinary ANDA pathway. The more relevant medium- and long-term risks are:
- A biosimilar application after the 12-year reference-product exclusivity period.
- Patent litigation over antibody, linker, payload, formulation, or process claims.
- Non-infringing biosimilar manufacturing processes.
- International biosimilar launches under different national exclusivity rules.
- Physician substitution pressure if an interchangeable product is approved.
- Price erosion from competing ADCs rather than from a direct biosimilar.
The most likely initial erosion pattern would be slower than for small-molecule generics. Hospital and oncology purchasing organizations may adopt lower-priced alternatives, but oncologist confidence, supply reliability, interchangeability status, and payer policy will influence substitution.
Key Takeaways
- Trodelvy is Gilead’s principal oncology growth asset and generated approximately $1 billion or more in annual sales by 2023.
- Its commercial base is metastatic triple-negative breast cancer, with additional exposure to HR-positive/HER2-negative disease.
- The U.S. urothelial-cancer indication became a material weakness after the TROPiCS-04 confirmatory failure.
- Gilead faces direct competition from datopotamab deruxtecan and indirect competition from Enhertu.
- FDA biologic exclusivity likely runs to approximately April 2032, subject to statutory and patent-law analysis.
- Patent protection is layered across the antibody, conjugate, linker, formulation, use, and manufacturing technologies.
- Near-term ANDA-based generic risk is low; future biosimilar and follow-on ADC risk is more significant.
- Long-term revenue growth depends on earlier-line breast-cancer expansion rather than urothelial cancer.
Frequently Asked Questions
Is Trodelvy a biologic or a small-molecule drug?
Trodelvy is a biologic antibody-drug conjugate. Its regulatory pathway is a BLA, and future competitors would generally pursue biosimilar approval rather than an ANDA.
Who owns the Trodelvy intellectual property?
Gilead Sciences owns and commercializes Trodelvy after acquiring Immunomedics in 2020. The relevant intellectual property originated largely from Immunomedics research and development programs.
Does Trodelvy have an Orange Book patent listing?
Trodelvy is regulated as a biologic, so the Orange Book is not the principal U.S. patent-listing framework. Biologic exclusivity and BPCIA patent procedures are more relevant.
What is the biggest threat to Trodelvy sales?
The largest commercial threats are Enhertu’s expansion in HER2-low and HER2-ultralow breast cancer and datopotamab deruxtecan’s direct competition in Trop-2-directed treatment.
Can Trodelvy reach multibillion-dollar annual sales?
It can reach materially higher sales if Gilead succeeds in earlier-line breast cancer and maintains efficacy-based differentiation. The failed urothelial confirmatory study reduces the probability of achieving the most aggressive peak-sales forecasts.
References
- U.S. Food and Drug Administration. (2020). FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple-negative breast cancer.
- Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., et al. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. New England Journal of Medicine, 384(16), 1529-1541.
- U.S. Food and Drug Administration. (2024). Definition of the term "biological product" and reference product exclusivity under the Biologics Price Competition and Innovation Act.
- Gilead Sciences, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Gilead Sciences, Inc. (2024). Gilead provides update on Trodelvy urothelial cancer indication following TROPiCS-04 results.
